Liposomal amphotericin B for the treatment of cryptococcal meningitis in HIV/AIDS patients in india-A pilot pharmacokinetic study

摘要

The liposomal formulation of amphotericin B greatly reduces side effects like nephrotoxicity. The present pilot study describes the pharmacokinetic characteristics of liposomal Amp B given to eight patients of cryptococcal meningitis with HIV/AIDS at a dose of 1 and 3 mg/kg/day. We observed that the pharmacokinetic parameters namely AUC, Cmax, CL, Vd, and half-life were not proportionate with 1 and 3 mg/kg/day dose of FungiosmeTM.With 1 and 3 mg/kg/day dose the mean Cmax was found to be 626.54 ± 39.26 and 1049.90 ± 742.75 ng/mL, respectively. In conclusion, liposomal Amp B was observed to be safe and efficacious in the treatment of cryptococcal meningitis in HIV/AIDS patients, however, a pharmacokinetics study with larger cohort of patients of cryptococcal meningitis in HIV AIDS is warranted